Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Genetic Predictors of Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer

Linda T. Hiraki, Conghui Qu, Carolyn M. Hutter, John A. Baron, Sonja I. Berndt, Stéphane Bézieau, Hermann Brenner, Bette J. Caan, Graham Casey, Jenny Chang-Claude, Stephen J. Chanock, David V. Conti, David Duggan, Charles S. Fuchs, Steven Gallinger, Edward L. Giovannucci, Tabitha A. Harrison, Richard B. Hayes, Aditi Hazra, Brian Henderson, Michael Hoffmeister, John L. Hopper, Thomas J. Hudson, Mark A. Jenkins, Sébastien Küry, Loic Le Marchand, Mathieu Lemire, Jing Ma, JoAnn E. Manson, Hongmei Nan, Polly A. Newcomb, Kimmie Ng, John D. Potter, Robert E. Schoen, Fredrick R. Schumacher, Daniela Seminara, Martha L. Slattery, Jean Wactawski-Wende, Emily White, Kana Wu, Brent W. Zanke, Peter Kraft, Ulrike Peters and Andrew T. Chan
Linda T. Hiraki
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conghui Qu
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn M. Hutter
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Baron
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonja I. Berndt
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Bézieau
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hermann Brenner
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bette J. Caan
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Casey
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Chang-Claude
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen J. Chanock
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David V. Conti
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Duggan
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles S. Fuchs
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Gallinger
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward L. Giovannucci
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tabitha A. Harrison
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard B. Hayes
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aditi Hazra
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Henderson
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Hoffmeister
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John L. Hopper
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Hudson
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Jenkins
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sébastien Küry
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loic Le Marchand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Lemire
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Ma
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JoAnn E. Manson
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongmei Nan
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Polly A. Newcomb
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimmie Ng
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Potter
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert E. Schoen
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fredrick R. Schumacher
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Seminara
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martha L. Slattery
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Wactawski-Wende
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily White
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kana Wu
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent W. Zanke
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Kraft
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Peters
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew T. Chan
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
' 1Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Departments of 2Nutrition, and 3Biostatistics, Harvard School of Public Health; 4Department of Medicine, and 5Channing Division of Network Medicine, Brigham and Women's Hospital; 6Division of Gastroenterology, Massachusetts General Hospital; 7Department of Medicine, Harvard Medical School; 8Gastrointestinal Malignancy Program, and 9Medical-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 10Public Health Sciences Division, Fred Hutchinson Cancer Research Center; 11Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington; 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Divisions of 13Cancer Epidemiology and Genetics, and 14Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda; 15University of Maryland, School of Medicine, Baltimore, Maryland; 16Service de Génétique Médicale, CHU Nantes, Nantes, France; Divisions of 17Clinical Epidemiology and Aging Research and 18Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany; 19Division of Research, Kaiser Permanente Medical Care Program, Oakland; 20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; 21Translational Genomics Research Institute, Phoenix, Arizona; 22Department of Surgery, Toronto General Hospital; 23Ontario Institute for Cancer Research; 24Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto; 25Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada; 26Department of Environmental Medicine, Division of Epidemiology, New York University School of Medicine, New York; 27Department of Social and Preventive Medicine, University of Buffalo, Buffalo, New York; 28Melborne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia; 29Epidemiology Program, Research Cancer Center of Hawaii, Honolulu, Hawaii; 30Department of Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 31Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah; and 32Centre for Public Health Research, Massey University, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-13-0209 Published November 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Experimental evidence has demonstrated an antineoplastic role for vitamin D in the colon, and higher circulating 25-hydroxyvitamin D [25(OH)D] levels are consistently associated with a lower risk of colorectal cancer. Genome-wide association studies have identified loci associated with levels of circulating 25(OH)D. The identified single-nucleotide polymorphisms (SNPs) from four gene regions collectively explain approximately 5% of the variance in circulating 25(OH)D.

Methods: We investigated whether five polymorphisms in GC, CYP2R1, CYP24A1, and DHCR7/NADSYN1, genes previously shown to be associated with circulating 25(OH)D levels, were associated with colorectal cancer risk in 10,061 cases and 12,768 controls drawn from 13 studies included in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and Colon Cancer Family Registry (CCFR). We conducted a meta-analysis of crude and multivariate-adjusted logistic regression models to calculate odds ratios and associated confidence intervals for SNPs individually, SNPs simultaneously, and for a vitamin D additive genetic risk score (GRS).

Results: We did not observe a statistically significant association between the 25(OH)D-associated SNPs and colorectal cancer marginally, conditionally, or as a GRS, or for colon or rectal cancer separately.

Conclusions: Our findings do not support an association between SNPs associated with circulating 25(OH)D and risk of colorectal cancer. Additional work is warranted to investigate the complex relationship between 25(OH)D and colorectal cancer risk.

Impact: There was no association observed between genetic markers of circulating 25(OH)D and colorectal cancer. These genetic markers account for a small proportion of the variance in 25(OH)D. Cancer Epidemiol Biomarkers Prev; 22(11); 2037–46. ©2013 AACR.

Introduction

Colorectal cancer is the second leading cause of cancer death in men and women in the United States. It is estimated that in 2013, a total of 142,820 U.S. men and women will be diagnosed with cancer of the colon and rectum (1). Family history is a strong risk factor for colorectal cancer (2, 3), which is consistent with the existence of shared etiologic and genetic determinants among relatives. Known genetic mutations account for about 30% to 50% of the familial risk (4); much of the remaining familial aggregation is unexplained. Genome-wide association studies (GWAS) of sporadic colorectal cancer have identified at least 20 independent loci statistically significantly associated with risk (5–12). However, these variants cumulatively explain only a very small fraction of colorectal cancer risk (13).

Beyond inherited risk, there is a large body of evidence supporting the role of nongenetic factors, including vitamin D status, in the etiology of colorectal cancer. The first human evidence to suggest an association between vitamin D and colorectal cancer was the ecologic study by Garland and Garland based on data collected in the 1950′s and 60′s which showed a strong inverse association between colon cancer mortality and solar UVB radiation exposure in the United States. (14). Since then, most but not all case–control and cohort studies have found an inverse association between intake of vitamin D (both diet and supplements) and colorectal cancer risk (15–18), with even stronger associations observed using directly measured circulating 25(OH)D (19–22), an integrated biomarker of vitamin D status (23). Randomized clinical trials of vitamin D supplementation, including the Women's Health Initiative (24) and the British Oxford Trial (25), have not showed reductions in colorectal cancer incidence. However, these trials have generally tested low doses of vitamin D and each included less than 7 years of follow-up, which is likely insufficient to show an effect on cancer incidence, particularly in light of the long latency of disease. Similarly, large meta-analyses of clinical trials have not shown robust evidence for a protective role of vitamin D in the development of colorectal cancer (26) despite some indication of a preventative role in the development of adenomas (27).

Circulating 25(OH)D levels are a function of dietary sources and exposure of the skin to sunlight, specifically UVB rays. In addition to environmental determinants, twin and family studies suggest that genetic factors contribute substantially to circulating vitamin D levels, with heritability estimates ranging from 43% to 80% (28–31).

Two published GWAS of 25(OH)D have uncovered single-nucleotide polymorphisms (SNPs) significantly associated with lower circulating 25(OH)D levels in four gene regions that seem to have functional relevance: GC (group-specific component vitamin D–binding protein); CYP2R1 (cytochrome P450, family 2, subfamily R, polypeptide 1), encoding C-25 hydroxylase that converts vitamin D to the active ligand for the vitamin D receptor; DHCR7/NADSYN1 [7-dehydrocholesterol (7-DHC) reductase/nicotinamide adenine dinucleotide synthetase] (32) with roles in the synthetic vitamin D pathway (33, 34); and CYP24A1 (encoding 24-hydroxylase involved in the degradation of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D; refs. 33, 34). Both the GC SNP rs2282679 and the DHCR7/NADSYN1 SNPs are located in intronic regions, with the GC SNP showing the largest magnitude of association with 25(OH)D < 75 nmol/L [odds ratios (OR), 1.63; 95% confidence intervals (CI), 1.53–1.73; ref. 34]. The SNP rs10741657 is proximal to the CYP2R1 gene and rs6013897 is proximal to CYP24A1 yet the precise associations with gene expression are yet to be determined.

We investigated the association between these SNPs previously identified as associated with 25(OH)D and risk of colorectal cancer in 13 cohorts that are part of the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR). Within a subset of participants from the Nurses' Health Study (NHS), Health Professionals Follow-up Study (HPFS), and Physician's Health Study (PHS) with measured prediagnostic plasma 25(OH)D levels, we also examined the joint effects of plasma 25(OH)D and 25(OH)D-associated SNPs on colorectal cancer risk.

Materials and Methods

Study population

The analysis included a total of 10,061 cases and 12,768 controls of European ancestry drawn from 13 studies within GECCO and CCFR. Details on the studies are provided in Table 1, and are described in detail in the Supplementary Data and Supplementary Table S1. In brief, each study defined colorectal cancer cases as colorectal adenocarcinoma, confirmed by medical records, pathologic reports, or death certificates. All participants provided informed consent and studies were approved by their respective Institutional Review Boards. None of the studies included in GECCO or CCFR contributed subjects to the any previous GWAS of 25(OH)D with the exception of a subset of the NHS subjects (n = 1,342) who participated in the validation stage of one study (33).

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of patients with colorectal cancer within included study populations

Genotyping, quality assurance/quality control, and imputation

We used genotype data from GECCO and CCFR. GECCO consisted of participants within the French Association Study Evaluating RISK for sporadic colorectal cancer (ASTERISK); Hawaii Colorectal Cancer Studies 2 and 3 (Colo2&3); Darmkrebs: Chancen der Verhütung durch Screening (DACHS); Diet, Activity, and Lifestyle Study (DALS); HPFS; Multiethnic Cohort (MEC); NHS; Ontario Familial Colorectal Cancer Registry (OFCCR); PHS; Prostate, Lung, Colorectal Cancer, and Ovarian Cancer Screening Trial (PLCO); VITamins And Lifestyle (VITAL); and the Women's Health Initiative (WHI). Phase I genotyping on a total of 1,709 colon cancer cases and 4,214 controls from PLCO, WHI, and DALS (PLCO Set 1, WHI Set 1, and DALS Set 1) was conducted using Illumina HumanHap 550 K, 610 K, or combined Illumina 300 K and 240 K, and has been described previously (12). A total of 650 colorectal cancer cases and 522 controls from OFCCR are included in GECCO from previous genotyping using Affymetrix platforms (35). A total of 5,540 colorectal cancer cases and 5,425 controls from ASTERISK, Colo2&3, DACHS, DALS Set 2, MEC, PMH, PLCO Set 2, VITAL, and WHI Set 2 were successfully genotyped using Illumina HumanCytoSNP. A total of 2,004 colorectal cancer colorectal cancer cases and 2,244 controls from HPFS (2 sets), NHS (2 sets), and PHS (2 sets) were successfully genotyped using Illumina HumanOmniExpress. The CCFR included a population-based case–control set of participants from sites in the United States, Canada, and Australia successfully genotyped using Illumina Human1M or Human1M-Duo (36).

DNA was extracted from samples of white blood cells or, in the case of a subset of NHS, HPFS, DACHS, MEC, and PLCO samples, and all VITAL samples from buccal cells using conventional methods (37). All studies included 1% to 6% blinded duplicates to monitor quality of the genotyping. All individual-level genotype data were managed centrally at University of Southern California (Los Angeles, CA; CCFR), the Ontario Institute for Cancer Research (Toronto, Ontario, Canada; OFCCR), the University of Washington (Seattle, WA; HPFS, NHS, and PHS), or the GECCO and CCFR Coordinating Center (CC) at the Fred Hutchinson Cancer Research Center (all other studies) to ensure consistent quality assurance and quality control and statistical analysis. Details on the quality assurance and quality control can be found in Supplementary Table S2. In brief, samples were excluded on the basis of call rate, heterozygosity, unexpected duplicates, gender discrepancy, and unexpectedly high identity-by-descent or unexpected concordance (>65%) with another individual. For missing SNP data, all GECCO studies were imputed to HapMap II release 24, with the exception of OFCCR, which was imputed to HapMap II release 22. CCFR was imputed using IMPUTE (38), OFCCR was imputed using BEAGLE (39), and all other studies were imputed using MACH (40). All SNPs met quality-control measures for Hardy–Weinberg equilibrium in controls (HWE; P ≥ 10−4) and minor allele frequency (MAF ≥ 1%) or imputation R2 > 0.3.

Dietary and lifestyle factors

Dietary information, including calcium, folate, fiber, and alcohol intake, was available for Colo2&3, DALS, HPFS, MEC, NHS, PLCO I, PLCO II, VITAL, WHI; calcium, folate, and alcohol was available in PHS; and calcium and alcohol in ASTERISK and DACHS. Regular use of nonsteroidal anti-inflammatory drugs (NSAID) was available for CCFR, Colo2&3, DACHS, HPFS, MEC, NHS, and VITAL. All studies collected data on smoking status, red meat consumption, physical activity, body mass index (BMI), and hormone replacement therapy in postmenopausal women with the exception of ASTERISK. ASTERISK was restricted to cases with no family history of colorectal cancer. We adopted a flexible approach to retrospective covariate harmonization as previously described (41, 42).

Laboratory assessment of 25(OH)D

In previous studies, we measured plasma levels of 25(OH)D in a subset of the cases and controls with genetic data that were nested within the NHS, HPFS, and PHS (total cases n = 672 and total controls n = 909) using a radioimmunosorbent assay in the laboratory of Dr. Bruce W. Hollis (Medical University of South Carolina, Charleston, SC). The median intra-assay coefficient of variation from blinded quality-control samples was 11.8% in NHS, 10.1% in HPFS, and 13.8% in PHS. Cases and their controls were analyzed in the same batch and laboratory personnel were blinded to case, control, and quality-control status (21, 43, 44).

Statistical analyses

The statistical analyses of the GECCO and CCFR samples were conducted at a central data analysis center on individual-level data to ensure a consistent analytic approach. For each study, we estimated the association between each SNP and risk for colorectal cancer by calculating βs, ORs, standard errors (SEs), 95% CIs, and P values using log-additive genetic models relating the genotype dose (0, 1, or 2 copies of the allele) to risk of colorectal cancer. For imputed SNPs, we used the dosage (expected number of copies of the minor allele) when testing associations, which has been shown to give unbiased estimates (45). We also created a genetic risk score (GRS), composed of four SNPs from four distinct gene regions to ensure no single gene was overrepresented in the score using an allelic scoring system based on summing the number of risk alleles [previously associated with lower 25(OH)D], yielding a possible range of 0 to 8 alleles to derive estimates of allelic OR.

Minimally adjusted models included covariates for age, sex (when appropriate), center (when appropriate), batch effects (ASTERISK only), and the first three principal components from EIGENSTRAT to account for population substructure. Multivariate models were additionally adjusted for family history of colorectal cancer, BMI, NSAID use, smoking status, alcohol use, dietary calcium, folate and red meat intake, sedentary status, and hormone replacement therapy based on covariate availability. We repeated the minimally adjusted model analyses stratified by anatomic site (colon and rectum).

We conducted inverse-variance weighted, fixed-effects meta-analysis to combine β estimates and SEs from log-additive models across individual studies. We chose to focus on fixed-effects to improve power and assessed heterogeneity across studies utilizing random effects models (46).

For analyses of the joint effect of plasma 25(OH)D and our GRS composed of 25(OH)D-associated SNPs, we included the 672 cases and 909 controls in NHS, HPFS, and PHS among whom we had previously measured prediagnostic levels of 25(OH)D and also had genotype data (21, 44). We calculated ORs and 95% CI for colorectal cancer comparing extreme quartiles of 25(OH)D defined according to cohort-specific cutoff points determined by the distribution in controls (44). We compared the GRS-associated risk for colorectal cancer across categories of high versus low vitamin D levels and quartiles of vitamin D, as well as tested for multiplicative interactions between GRS and a 1 ng/mL increase in 25(OH)D and high/low vitamin D using a product term in the model and assessing its significance by the Wald method.

We used PLINK, R (47, 48), and SAS 9.2 (SAS Institute, Inc.) to conduct the statistical analyses. We estimated our power to detect an association between a GRS and colorectal cancer using the method of Tosteson and colleagues. (49). These calculations account for the strength of association between the vitamin D SNPs and circulating 25(OH)D.

Results

Our study included 10,061 colorectal cancer cases and 12,768 controls. Overall 53% were female and the mean age at colorectal cancer diagnosis was 64 years (±9.6 SD), 55.0% past/current smokers and with risk allele frequencies ranging from 16% to 61%. Table 1 summarizes the characteristics of the studies included in the analyses. Analyses of each individual SNP in models first minimally and then fully adjusted, did not show a statistically significant association with colorectal cancer risk (Table 2). In analyses stratified by anatomic site, each of the five SNP associations remained nonsignificant (Table 3), in tests of associations with cancers of the colon and rectum.

View this table:
  • View inline
  • View popup
Table 2.

Association between five 25(OH)D-associated SNPs and colorectal cancer among 10,061 cases and 12,768 controls

View this table:
  • View inline
  • View popup
Table 3.

Association between five 25(OH)D-associated SNPs and colorectal cancer stratified by site

We considered the possibility that a combination of SNPs associated with circulating 25(OH)D in prior GWAS may be associated with risk of colorectal cancer. However, an analysis of a GRS composed of the risk alleles from the four SNPs associated with plasma 25(OH)D and colorectal cancer risk did not show any significant association (Table 4). The Fig. 1 forest plot depicts the ORs and 95% CIs of the GRS and colorectal cancer association of the individual GECCO and CCFR studies showing a balanced distribution of study-specific ORs around the null value of 1.0.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Forest plot of the GRS and colorectal cancer for individual studies and meta-analysis of all studies (allelic OR, 95% CI).

View this table:
  • View inline
  • View popup
Table 4.

Association between four mutually adjusted 25(OH)D-associated SNPs, a composite SNP additive GRS and colorectal cancer

Among the subset of NHS, HPFS, and PHS subjects with measured prediagnostic plasma 25(OH)D levels (N = 672 cases and N = 909 controls), we observed that a one-allele change in our GRS was associated with a mean 1.5 ng/mL decrease in 25(OH)D (P < 0.0001). Compared with the lowest quartile of 25(OH)D, the highest quartile of 25(OH)D was associated with an OR of 0.66 (95% CI, 0.47–0.92) for colorectal cancer. We did not observe a differential association of GRS with risk of colorectal cancer according to strata of quartile levels of plasma 25(OH)D or according to high or low levels of 25(OH)D (Pheterogeneity > 0.05).

Discussion

Consistent evidence from epidemiologic studies supports an inverse association between circulating 25(OH)D, the best integrated biomarker of vitamin D status, and risk of colorectal cancer. However, contrary to expectation, we did not observe a statistically significant association between SNPs associated with circulating 25(OH)D and colorectal cancer, marginally or in an additive GRS.

A number of epidemiologic studies have reported inverse associations between 25(OH)D and colorectal cancer. A meta-analysis of five nested case–control studies reported a pooled OR of 0.49 (95% CI, 0.35–0.68) for colorectal cancer comparing the highest quintile (median 37 ng/mL) of 25(OH)D with the lowest (6 ng/mL) (19). Another recent systematic review of nine studies observed a pooled relative risk (RR) for colorectal cancer of 0.67 (95% CI, 0.54–0.80) comparing extreme quintiles of 25(OH)D (22). Overall, the estimated OR of colorectal cancer for a 10 ng/mL increase in circulating 25(OH)D was 0.74 (95% CI, 0.63–0.89) with the relationship appearing approximately linear (22). Several mechanisms could explain an anticancer benefit for vitamin D: reduction of cell proliferation; inhibition of angiogenesis; promotion of cell differentiation; and stimulation of apoptosis (23, 50–57). Vitamin D also has an anti-inflammatory effect, reducing PTGS-2 (COX-2) expression and decreasing levels of the inflammatory marker C-reactive protein (58–60).

Prior clinical trials testing the association between vitamin D and cancer have been null. In a 5-year British placebo-controlled trial with cancer assessed as a secondary outcome, 100,000 IU of vitamin D3 every 4 months over 5 years was not associated with colorectal cancer incidence (RR = 1.02; 95% CI, 0.60–1.74; 25). Similarly, among 36,000 women in the WHI calcium–vitamin D trial, a combination of calcium (1,000 mg/day) plus low-dose vitamin D3 (400 IU/day) for a mean of 7 years did not reduce colorectal cancer incidence (RR = 1.08; 95% CI, 0.86–1.34; 24). However, the interpretation of these null results is tempered by several important limitations. First, the relatively low doses of vitamin D used were probably inadequate to yield a substantial contrast between the treatment and placebo groups. Second, the duration of follow-up was probably too short to observe an influence on incidence of cancer. Observational data suggest that any influence of calcium and vitamin D intake on colorectal cancer risk could require at least 10 years to emerge, consistent with our understanding of the prolonged dwell time of the adenoma–carcinoma pathway (18). On the other hand, a Nebraska population-based placebo-controlled trial of calcium alone or calcium plus vitamin D3 (1,100 IU/day) observed a significantly lower cancer incidence among those supplemented with calcium and vitamin D over just 4 years of treatment (61). However, follow-up of total cancers was a secondary outcome and there were only a small number of colorectal cancer cases, limiting the interpretation of these results.

More than 90% of circulating 25(OH)D is protein-bound with the GC encoded vitamin D–binding protein being the major carrier of 25(OH)D. Less than 1% of vitamin D circulates in its unbound form (62). Vitamin D–binding protein is a multifunctional protein that also binds fatty acids and may have immune functions independent of its role as a carrier of vitamin D (63). Prior studies have observed that unbound 25(OH)D was more strongly related to bone mineral density (64) and parathyroid hormone levels among hemodialized patients (65), than total 25(OH)D, thereby implicating a role for vitamin D–binding protein in modifying the biologic activity of circulating vitamin D. The available estimates of the association between 25(OH)D and colorectal cancer, as well as genetic markers of 25(OH)D, are based solely on total circulating 25(OH)D levels (19, 22, 33, 34). It is unclear how these estimates might change when accounting for vitamin D–binding protein levels or by individually examining free and protein-bound 25(OH)D.

Prior studies have examined individual SNPs in CYP24A1 or GC (66, 67) in association with risk of colorectal cancer. A prior DALS multicenter population-based case–control study of 1,600 colorectal cancer cases found a statistically significant association between one CYP24A1 polymorphism and overall risk of colon cancer, particularly for proximal colon cancer, as well as an association between three CYP24A1 polymorphisms and distal colon cancer (67). However, the correlation between these CYP24A1 genetic markers investigated by the DALS study and the CYP24A1 marker examined in this full combined analysis study is very low (r2 < 0.1). Because our a priori hypothesis was that SNPs most strongly associated with 25(OH)D levels would be associated with colorectal cancer, we did not consider total genetic variation in CYP24A1 with colorectal cancer risk. It is possible that alternative CYP24A1 SNPs may be associated with colorectal cancer through mechanisms independent of 25(OH) D levels. A prior study of the CCFR cohort of 1,750 sibships found no evidence for associations between GC and the risk of colorectal cancer and no evidence for modification of the association by calcium and/or vitamin D intake (66). Studies of additional genes that are not significantly associated with circulating 25(OH)D but are implicated in the vitamin D pathway, including the vitamin D receptor (VDR) SNPs Fok1 and BsmI, have yielded inconsistent results (68–71).

The lack of association that we observed between genetic markers associated with circulating 25(OH)D and colorectal cancer is consistent with prior clinical trials of vitamin D and colorectal cancer and would, at least initially, seem to argue against a causal association between vitamin D and colorectal cancer (72). However, prior work has showed that these 4 SNPs, although correlated with circulating 25(OH)D, explain only a small fraction (5%) of the variance in circulating 25(OH) (73). Recently, a Scottish case–control study observed a significant association between direct plasma measurements of 25(OH)D and colorectal cancer risk, yet failed to replicate the association using an instrumental-variable method of Mendelian randomization with the same four genome-wide significant risk loci examined in our analysis (74). The investigators attributed these inconsistent results to a presumed weak correlation between these SNPs and 25(OH)D, as well as a limited sample size of 2,001 cases of colorectal cancer and 2,237 controls. Given our significantly larger sample size of approximately 10,000 cases and 12,500 controls and assuming a correlation between our GRS and 25(OH)D of r = 0.17, with a 10 ng/mL increase in 25(OH)D associated with OR = 0.74 for colorectal cancer (22), our power to detect a one-allele change in our GRS is 96% (significance level of 0.05). However, if the true magnitude of association with a 10 ng/mL increase in 25(OH)D is in fact an OR of 0.85 for colorectal cancer, we would have only had 56% power to detect a one-allele change in our GRS.

We are not certain of the precise pathway or biologic mediators by which 25(OH)D influences colorectal cancer risk. Our GRS assumes that each included SNP would be associated with increased colorectal cancer risk according to their observed association with lower 25(OH)D. If this assumption is invalid, combining the alleles into this GRS would reduce our power to detect associations with colorectal cancer. If we remove the GC SNP and repeat our power calculation, our observed correlation between our GRS and 25(OH)D becomes r = 0.11, resulting in 68% power to detect a one-allele change in our proxy score.

We acknowledge some limitations. First, our study includes only populations of European descent, which limits the generalizability of our findings. However, the circulating 25(OH)D SNPs that we examined were identified in GWAS of populations of European descent and so the underlying genetic associations should hold in our study population. Moreover, limiting our analysis to European descent populations minimizes the potential for confounding by population structure. Second, if these SNPs are correlated with another locus that influences the risk of colorectal cancer, this could confound our results (72). Third, despite our large sample size, we had limited power to detect associations between individual SNPs and risk of colorectal cancer.

In conclusion, our findings do not support an association between SNPs associated with circulating 25(OH)D and risk of colorectal cancer. This may be due to the fact that these SNPs account for only a small portion of the variance observed in circulating 25(OH)D levels and that those alleles associated with low-circulating levels of 25(OH)D may not affect colorectal cancer risk in the same direction. Future studies are needed to examine the role of unbound and protein-bound 25(OH)D, along with other biomarkers of the vitamin D pathway, in the development of colorectal cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: L.T. Hiraki, C.M. Hutter, B.J. Caan, C.S. Fuchs, E. Giovannucci, J.L. Hopper, D. Seminara, P. Kraft, U. Peters, A.T. Chan

Development of methodology: S.J. Chanock, D. Duggan, C.S. Fuchs, A. Hazra, J.L. Hopper, P. Kraft, U. Peters, A.T. Chan

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.M. Hutter, S.I. Berndt, S. Bézieau, H. Brenner, B.J. Caan, G. Casey, J. Chang-Claude, S.J. Chanock, D.V. Conti, D. Duggan, C.S. Fuchs, S. Gallinger, R. Hayes, M. Hoffmeister, T.J. Hudson, M.A. Jenkins, S. Küry, L. Le Marchand, J. Ma, J.E. Manson, P.A. Newcomb, K. Ng, J.D. Potter, R.E. Schoen, M.L. Slattery, J. Wactawski-Wende, E. White, B.W. Zanke, U. Peters, A.T. Chan

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.T. Hiraki, C. Qu, C.M. Hutter, D.V. Conti, C.S. Fuchs, E. Giovannucci, A. Hazra, J.L. Hopper, M Lemire, J.E. Manson, H. Nan, P.A. Newcomb, K. Ng, F. Schumacher, K. Wu, P. Kraft, U. Peters, A.T. Chan

Writing, review, and/or revision of the manuscript: L.T. Hiraki, C. Qu, C.M. Hutter, J.A. Baron, S.I. Berndt, S. Bézieau, H. Brenner, G. Casey, J. Chang-Claude, C.S. Fuchs, E. Giovannucci, R. Hayes, A. Hazra, B. Henderson, M. Hoffmeister, J.L. Hopper, T.J. Hudson, M.A. Jenkins, S. Küry, L. Le Marchand, J. Ma, J.E. Manson, P.A. Newcomb, K. Ng, J.D. Potter, R.E. Schoen, F. Schumacher, D. Seminara, M.L. Slattery, J. Wactawski-Wende, E. White, K. Wu, P. Kraft, U. Peters, A.T. Chan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.T. Hiraki, C. Qu, T.A. Harrison, M. Hoffmeister, S. Küry, L. Le Marchand, J.E. Manson, F. Schumacher, P. Kraft, U. Peters, A.T. Chan

Study supervision: C.S. Fuchs, M. Hoffmeister, J. Wactawski-Wende, P. Kraft, U. Peters, A.T. Chan

Grant Support

S. Bézieau and S. Kury are affiliated with ASTERISK which was funded by a regional Programme Hospitalier de Recherche Clinique (PHRC) and supported by the Regional Council of Pays de la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Génétique, and the Ligue Régionale Contre le Cancer (LRCC).

J.A. Baron, G. Casey, D.V. Conti, J.L. Hopper, M.A. Jenkins, P.A. Newcomb, and F.R. Schumacher are affiliated with CCFR which is supported by the National Cancer Institute, NIH under RFA # CA-95-011 and through cooperative agreements with members of the CCFR and principal investigators (P.I.s). This genome wide scan was supported by the National Cancer Institute, NIH by U01 CA122839. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFRs, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the CFR. The following CCFR centers contributed data to this article and were supported by the following sources: Australasian Colorectal Cancer Family Registry (U01 CA097735), Seattle Colorectal Cancer Family Registry (U01 CA074794), and Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783).

S. Gallinger, T.J. Hudson, M. Lemire, and B.W. Zanke are affiliated with OFCCR which is supported by the NIH, through funding allocated to the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783); see CCFR section above. As subset of ARCTIC, OFCCR is supported by a GL2 grant from the Ontario Research Fund, the Canadian Institutes of Health Research, and the Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society Research Institute. T.J. Hudson and B.W. Zanke are recipients of Senior Investigator Awards from the Ontario Institute for Cancer Research, through generous support from the Ontario Ministry of Research and Innovation.

B. Henderson and L. Le Marchand are affiliated with COLO2&3/MEC. COLO2&3 is supported by the National Cancer Institute (R01 CA60987). MEC is supported by R37 CA54281, P01 CA033619, and R01 CA63464.

H. Brenner, J. Chang-Claude, and M. Hoffmeister are affiliated with DACHS which was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, and CH 117/1-1), and the German Federal Ministry of Education and Research (01KH0404 and 01ER0814).

B.J. Caan, J.D. Potter, and M.L. Slattery are affiliated with DALS which was supported by the National Cancer Institute, NIH, U.S. Department of Health and Human Services (R01 CA48998 to M.L. Slattery).

T.A. Harrison, C.M. Hutter, U. Peters, and C. Qu are affiliated with GECCO which is supported by National Cancer Institute, NIH, U.S. Department of Health and Human Services (U01 CA137088). Funding for the genome-wide scan of DALS, PLCO, and WHI was provided by the National Cancer Institute, NIH, U.S. Department of Health and Human Services (R01 CA059045).

A.T. Chan, C.S. Fuchs, E.L. Giovannucci, L.T. Hiraki, A. Hazra, P. Kraft, H. Nan, K. Ng, and K. Wu are affiliated with HPFS, NHS, and PHS. HPFS was supported by the NIH (P01 CA 055075, UM1 CA167552, R01 137178, and P50 CA 127003), NHS by the NIH (R01 137178, P50 CA 127003, and P01 CA 087969) and PHS by the NIH (CA42182). A.T. Chan is a Damon Runyon Clinical Investigator and also supported by K24 DK098311. L. T. Hiraki was supported by a Canadian Institute of Health Research (CIHR) Fellowship Award.

S.I. Berndt, S.J. Chanock, R.B. Hayes, and R.E. Schoen are affiliated with PLCO which was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. Control samples were genotyped as part of the Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer scan, supported by the Intramural Research Program of the National Cancer Institute. The datasets used in this analysis were accessed with appropriate approval through the dbGaP online resource (http://www.cgems.cancer.gov/data_acess.html) through dbGaP accession number 000207v.1p1.c1. [National Cancer Institute (2009) CGEMS data website. http://cgems.cancer.gov/data_access.html; ref. 75]. Control samples were also genotyped as part of the GWAS of Lung Cancer and Smoking [76]. Funding for this work was provided through the NIH, Genes, Environment and Health Initiative [NIH GEI] (Z01 CP 010200). The human subjects participating in the GWAS are derived from the Prostate, Lung, Colon and Ovarian Screening Trial and the study is supported by intramural resources of the National Cancer Institute. Assistance with genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies, GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Funding support for genotyping, which was conducted at the Center for Inherited Disease Research, Johns Hopkins University (Baltimore, MD) was provided by the NIH GEI (U01 HG 004438). The datasets used for the analyses described in this article were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000093.

E. White is affiliated with VITAL which is supported in part by the NIH (K05 CA154337) from the National Cancer Institute and Office of Dietary Supplements.

J. Manson and J. Wactawski-Wende are affiliated with WHI. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

  • Received March 22, 2013.
  • Revision received July 19, 2013.
  • Accepted July 31, 2013.
  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. Howlader N,
    2. Noone A,
    3. Krapcho M,
    4. Neyman N,
    5. Aminou R,
    6. Waldron W,
    7. et al.
    , editors. In: SEER cancer statistics review, 1975–2010. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2010/.
  2. 2.↵
    1. Johns LE,
    2. Houlston RS
    . A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001;96:2992–3003.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Baglietto L,
    2. Jenkins MA,
    3. Severi G,
    4. Giles GG,
    5. Bishop DT,
    6. Boyle P,
    7. et al.
    Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol 2006;59:114–24.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Aaltonen L,
    2. Johns L,
    3. Jarvinen H,
    4. Mecklin JP,
    5. Houlston R
    . Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 2007;13:356–61.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Tenesa A,
    2. Theodoratou E,
    3. Din FV,
    4. Farrington SM,
    5. Cetnarskyj R,
    6. Barnetson RA,
    7. et al.
    Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin Cancer Res 2010;16:3754–9.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Houlston RS,
    2. Webb E,
    3. Broderick P,
    4. Pittman AM,
    5. Di Bernardo MC,
    6. Lubbe S,
    7. et al.
    Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008;40:1426–35.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Houlston RS,
    2. Cheadle J,
    3. Dobbins SE,
    4. Tenesa A,
    5. Jones AM,
    6. Howarth K,
    7. et al.
    Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010;42:973–7.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Tomlinson IP,
    2. Webb E,
    3. Carvajal-Carmona L,
    4. Broderick P,
    5. Howarth K,
    6. Pittman AM,
    7. et al.
    A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008;40:623–30.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Tomlinson IP,
    2. Carvajal-Carmona LG,
    3. Dobbins SE,
    4. Tenesa A,
    5. Jones AM,
    6. Howarth K,
    7. et al.
    Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet 2011;7:e1002105.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Kocarnik JD,
    2. Hutter CM,
    3. Slattery ML,
    4. Berndt SI,
    5. Hsu L,
    6. Duggan DJ,
    7. et al.
    Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:3131–9.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Hutter CM,
    2. Slattery ML,
    3. Duggan DJ,
    4. Muehling J,
    5. Curtin K,
    6. Hsu L,
    7. et al.
    Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. BMC Cancer 2010;10:670.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Dunlop MG,
    2. Dobbins SE,
    3. Farrington SM,
    4. Jones AM,
    5. Palles C,
    6. Whiffin N,
    7. et al.
    Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012;44:770–6.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Galvan A,
    2. Ioannidis JP,
    3. Dragani TA
    . Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010;26:132–41.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Garland CF,
    2. Garland FC
    . Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227–31.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Garland C,
    2. Shekelle RB,
    3. Barrett-Connor E,
    4. Criqui MH,
    5. Rossof AH,
    6. Paul O
    . Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;1:307–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Kearney J,
    2. Giovannucci E,
    3. Rimm EB,
    4. Ascherio A,
    5. Stampfer MJ,
    6. Colditz GA,
    7. et al.
    Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol 1996;143:907–17.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Bostick RM,
    2. Potter JD,
    3. Sellers TA,
    4. McKenzie DR,
    5. Kushi LH,
    6. Folsom AR
    . Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol 1993;137:1302–17.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Martinez ME,
    2. Giovannucci EL,
    3. Colditz GA,
    4. Stampfer MJ,
    5. Hunter DJ,
    6. Speizer FE,
    7. et al.
    Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst 1996;88:1375–82.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Gorham ED,
    2. Garland CF,
    3. Garland FC,
    4. Grant WB,
    5. Mohr SB,
    6. Lipkin M,
    7. et al.
    Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007;32:210–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Woolcott CG,
    2. Wilkens LR,
    3. Nomura AM,
    4. Horst RL,
    5. Goodman MT,
    6. Murphy SP,
    7. et al.
    Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2010;19:130–4.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Wu K,
    2. Feskanich D,
    3. Fuchs CS,
    4. Willett WC,
    5. Hollis BW,
    6. Giovannucci EL
    . A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007;99:1120–9.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Ma Y,
    2. Zhang P,
    3. Wang F,
    4. Yang J,
    5. Liu Z,
    6. Qin H
    . Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011;29:3775–82.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Holick MF
    . Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S–88S.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Wactawski-Wende J,
    2. Kotchen JM,
    3. Anderson GL,
    4. Assaf AR,
    5. Brunner RL,
    6. O'Sullivan MJ,
    7. et al.
    Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684–96.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Trivedi DP,
    2. Doll R,
    3. Khaw KT
    . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Chung M,
    2. Lee J,
    3. Terasawa T,
    4. Lau J,
    5. Trikalinos TA
    . Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:827–38.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Carroll C,
    2. Cooper K,
    3. Papaioannou D,
    4. Hind D,
    5. Pilgrim H,
    6. Tappenden P
    . Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin Ther 2010;32:789–803.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Wjst M,
    2. Altmuller J,
    3. Braig C,
    4. Bahnweg M,
    5. Andre E
    . A genome-wide linkage scan for 25-OH-D(3) and 1,25-(OH)2-D3 serum levels in asthma families. J Steroid Biochem Mol Biol 2007;103:799–802.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Orton SM,
    2. Morris AP,
    3. Herrera BM,
    4. Ramagopalan SV,
    5. Lincoln MR,
    6. Chao MJ,
    7. et al.
    Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008;88:441–7.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Hunter D,
    2. De Lange M,
    3. Snieder H,
    4. MacGregor AJ,
    5. Swaminathan R,
    6. Thakker RV,
    7. et al.
    Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 2001;16:371–8.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Shea MK,
    2. Benjamin EJ,
    3. Dupuis J,
    4. Massaro JM,
    5. Jacques PF,
    6. D'Agostino RB Sr.,
    7. et al.
    Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr 2009;63:458–64.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Banach-Petrosky W,
    2. Ouyang X,
    3. Gao H,
    4. Nader K,
    5. Ji Y,
    6. Suh N,
    7. et al.
    Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006;12:5895–901.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Ahn J,
    2. Yu K,
    3. Stolzenberg-Solomon R,
    4. Simon KC,
    5. McCullough ML,
    6. Gallicchio L,
    7. et al.
    Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010;19:2739–45.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Wang TJ,
    2. Zhang F,
    3. Richards JB,
    4. Kestenbaum B,
    5. van Meurs JB,
    6. Berry D,
    7. et al.
    Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010;376:180–8.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Zanke BW,
    2. Greenwood CM,
    3. Rangrej J,
    4. Kustra R,
    5. Tenesa A,
    6. Farrington SM,
    7. et al.
    Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007;39:989–94.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Figueiredo JC,
    2. Lewinger JP,
    3. Song C,
    4. Campbell PT,
    5. Conti DV,
    6. Edlund CK,
    7. et al.
    Genotype-environment interactions in microsatellite stable/microsatellite instability-low colorectal cancer: results from a genome-wide association study. Cancer Epidemiol Biomarkers Prev 2011;20:758–66.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. King IB,
    2. Satia-Abouta J,
    3. Thornquist MD,
    4. Bigler J,
    5. Patterson RE,
    6. Kristal AR,
    7. et al.
    Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev 2002;11(10 Pt 1):1130–3.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Marchini J,
    2. Howie B,
    3. Myers S,
    4. McVean G,
    5. Donnelly P
    . A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007;39:906–13.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Browning SR,
    2. Browning BL
    . Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 2007;81:1084–97.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Li Y,
    2. Willer CJ,
    3. Ding J,
    4. Scheet P,
    5. Abecasis GR
    . MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34:816–34.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Hutter CM,
    2. Chang-Claude J,
    3. Slattery ML,
    4. Pflugeisen BM,
    5. Lin Y,
    6. Duggan D,
    7. et al.
    Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res 2012;72:2036–44. E
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Fortier I,
    2. Doiron D,
    3. Little J,
    4. Ferretti V,
    5. L'Heureux F,
    6. Stolk RP,
    7. et al.
    Is rigorous retrospective harmonization possible? Application of the DataSHaPER approach across 53 large studies. Int J Epidemiol 2011;40:1314–28.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Feskanich D,
    2. Ma J,
    3. Fuchs CS,
    4. Kirkner GJ,
    5. Hankinson SE,
    6. Hollis BW,
    7. et al.
    Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502–8.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Lee JE,
    2. Li H,
    3. Chan AT,
    4. Hollis BW,
    5. Lee IM,
    6. Stampfer MJ,
    7. et al.
    Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res (Phila) 2011;4:735–43.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Jiao S,
    2. Hsu L,
    3. Hutter CM,
    4. Peters U
    . The use of imputed values in the meta-analysis of genome-wide association studies. Genet Epidemiol 2011;35:597–605.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Kraft P,
    2. Zeggini E,
    3. Ioannidis JP
    . Replication in genome-wide association studies. Stat Sci 2009;24:561–73.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Purcell S,
    2. Neale B,
    3. Todd-Brown K,
    4. Thomas L,
    5. Ferreira MA,
    6. Bender D,
    7. et al.
    PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–75.
    OpenUrlCrossRefPubMed
  48. 48.↵
    R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
  49. 49.↵
    1. Tosteson TD,
    2. Buzas JS,
    3. Demidenko E,
    4. Karagas M
    . Power and sample size calculations for generalized regression models with covariate measurement error. Stat Med 2003;22:1069–82.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Newmark HL,
    2. Yang K,
    3. Kurihara N,
    4. Fan K,
    5. Augenlicht LH,
    6. Lipkin M
    . Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 2009;30:88–92.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Arnson Y,
    2. Amital H,
    3. Shoenfeld Y
    . Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007;66:1137–42.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Yang K,
    2. Yang W,
    3. Mariadason J,
    4. Velcich A,
    5. Lipkin M,
    6. Augenlicht L
    . Dietary components modify gene expression: implications for carcinogenesis. J Nutr 2005;135:2710–4.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Toubi E,
    2. Shoenfeld Y
    . The role of vitamin D in regulating immune responses. Isr Med Assoc J 2010;12:174–5.
    OpenUrlPubMed
  54. 54.↵
    1. Erdelyi I,
    2. Levenkova N,
    3. Lin EY,
    4. Pinto JT,
    5. Lipkin M,
    6. Quimby FW,
    7. et al.
    Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer. J Nutr 2009;139:2072–8.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Diaz GD,
    2. Paraskeva C,
    3. Thomas MG,
    4. Binderup L,
    5. Hague A
    . Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304–12.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Giuliano AR,
    2. Franceschi RT,
    3. Wood RJ
    . Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. Arch Biochem Biophys 1991;285:261–9.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Miller EA,
    2. Keku TO,
    3. Satia JA,
    4. Martin CF,
    5. Galanko JA,
    6. Sandler RS
    . Calcium, vitamin D, and apoptosis in the rectal epithelium. Cancer Epidemiol Biomarkers Prev 2005;14:525–8.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Fichera A,
    2. Little N,
    3. Dougherty U,
    4. Mustafi R,
    5. Cerda S,
    6. Li YC,
    7. et al.
    A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J Surg Res 2007;142:239–45.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Timms PM,
    2. Mannan N,
    3. Hitman GA,
    4. Noonan K,
    5. Mills PG,
    6. Syndercombe-Court D,
    7. et al.
    Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002;95:787–96.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Krishnan AV,
    2. Feldman D
    . Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011;51:311–36.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Lappe JM,
    2. Travers-Gustafson D,
    3. Davies KM,
    4. Recker RR,
    5. Heaney RP
    . Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586–91.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Bikle DD,
    2. Siiteri PK,
    3. Ryzen E,
    4. Haddad JG
    . Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab 1985;61:969–75.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Chun RF
    . New perspectives on the vitamin D binding protein. Cell Biochem Funct 2012;30:445–56.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Powe CE,
    2. Ricciardi C,
    3. Berg AH,
    4. Erdenesanaa D,
    5. Collerone G,
    6. Ankers E,
    7. et al.
    Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011;26:1609–16.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Bhan I,
    2. Powe CE,
    3. Berg AH,
    4. Ankers E,
    5. Wenger JB,
    6. Karumanchi SA,
    7. et al.
    Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012;82:84–9.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Poynter JN,
    2. Jacobs ET,
    3. Figueiredo JC,
    4. Lee WH,
    5. Conti DV,
    6. Campbell PT,
    7. et al.
    Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2010;19:525–36.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Dong LM,
    2. Ulrich CM,
    3. Hsu L,
    4. Duggan DJ,
    5. Benitez DS,
    6. White E,
    7. et al.
    Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:2540–8.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Ochs-Balcom HM,
    2. Cicek MS,
    3. Thompson CL,
    4. Tucker TC,
    5. Elston RC,
    6. S JP,
    7. et al.
    Association of vitamin D receptor gene variants, adiposity and colon cancer. Carcinogenesis 2008;29:1788–93.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Park K,
    2. Woo M,
    3. Nam J,
    4. Kim JC
    . Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Lett 2006;237:199–206.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Wong HL,
    2. Seow A,
    3. Arakawa K,
    4. Lee HP,
    5. Yu MC,
    6. Ingles SA
    . Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 2003;24:1091–5.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    1. Touvier M,
    2. Chan DS,
    3. Lau R,
    4. Aune D,
    5. Vieira R,
    6. Greenwood DC,
    7. et al.
    Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1003–16.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Sheehan NA,
    2. Didelez V,
    3. Burton PR,
    4. Tobin MD
    . Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008;5:e177.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Hiraki LT,
    2. Major JM,
    3. Chen C,
    4. Cornelis MC,
    5. Hunter DJ,
    6. Rimm EB,
    7. et al.
    Exploring the genetic architecture of circulating 25-hydroxyvitamin D. Genet Epidemiol 2013;37:92–8.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Theodoratou E,
    2. Palmer T,
    3. Zgaga L,
    4. Farrington SM,
    5. McKeigue P,
    6. Din FV,
    7. et al.
    Instrumental variable estimation of the causal effect of plasma 25-hydroxy-vitamin d on colorectal cancer risk: a mendelian randomization analysis. PLoS ONE 2012;7:e37662.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Yeager M,
    2. Orr N,
    3. Hayes RB,
    4. Jacobs KB,
    5. Kraft P,
    6. Wacholder S,
    7. et al.
    Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645–9.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Landi MT,
    2. Chatterjee N,
    3. Yu K,
    4. Goldin LR,
    5. Goldstein AM,
    6. Rotunno M,
    7. et al.
    A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009;85:679–91.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 22 (11)
November 2013
Volume 22, Issue 11
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Genetic Predictors of Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Genetic Predictors of Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer
Linda T. Hiraki, Conghui Qu, Carolyn M. Hutter, John A. Baron, Sonja I. Berndt, Stéphane Bézieau, Hermann Brenner, Bette J. Caan, Graham Casey, Jenny Chang-Claude, Stephen J. Chanock, David V. Conti, David Duggan, Charles S. Fuchs, Steven Gallinger, Edward L. Giovannucci, Tabitha A. Harrison, Richard B. Hayes, Aditi Hazra, Brian Henderson, Michael Hoffmeister, John L. Hopper, Thomas J. Hudson, Mark A. Jenkins, Sébastien Küry, Loic Le Marchand, Mathieu Lemire, Jing Ma, JoAnn E. Manson, Hongmei Nan, Polly A. Newcomb, Kimmie Ng, John D. Potter, Robert E. Schoen, Fredrick R. Schumacher, Daniela Seminara, Martha L. Slattery, Jean Wactawski-Wende, Emily White, Kana Wu, Brent W. Zanke, Peter Kraft, Ulrike Peters and Andrew T. Chan
Cancer Epidemiol Biomarkers Prev November 1 2013 (22) (11) 2037-2046; DOI: 10.1158/1055-9965.EPI-13-0209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Genetic Predictors of Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer
Linda T. Hiraki, Conghui Qu, Carolyn M. Hutter, John A. Baron, Sonja I. Berndt, Stéphane Bézieau, Hermann Brenner, Bette J. Caan, Graham Casey, Jenny Chang-Claude, Stephen J. Chanock, David V. Conti, David Duggan, Charles S. Fuchs, Steven Gallinger, Edward L. Giovannucci, Tabitha A. Harrison, Richard B. Hayes, Aditi Hazra, Brian Henderson, Michael Hoffmeister, John L. Hopper, Thomas J. Hudson, Mark A. Jenkins, Sébastien Küry, Loic Le Marchand, Mathieu Lemire, Jing Ma, JoAnn E. Manson, Hongmei Nan, Polly A. Newcomb, Kimmie Ng, John D. Potter, Robert E. Schoen, Fredrick R. Schumacher, Daniela Seminara, Martha L. Slattery, Jean Wactawski-Wende, Emily White, Kana Wu, Brent W. Zanke, Peter Kraft, Ulrike Peters and Andrew T. Chan
Cancer Epidemiol Biomarkers Prev November 1 2013 (22) (11) 2037-2046; DOI: 10.1158/1055-9965.EPI-13-0209
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement